| . | Cure (n = 78) . | No Cure (n = 60) . | P . | Odds Ratio . | 95% CI . |
|---|---|---|---|---|---|
| Age at presentation, median (IQR), y | 61.5 (54.0, 71.2) | 62.2 (55.0, 70.7) | .986 | 1.000 | (.977, 1.024) |
| Female, n (%) | 54 (69.2) | 40 (66.7) | .854 | 1.125 | (.547, 2.313) |
| BMI, median (IQR), kg/m2 | 22.4 (19.1, 24.7) | 22.1 (19.5, 25.7) | .467 | 1.026 | (.957, 1.098) |
| Race/ethnicity, n (%) | |||||
| Non-Hispanic white | 47 (60.3) | 35 (58.3) | .396 | … | … |
| Non-Hispanic black | 6 (7.7) | 2 (3.3) | … | … | |
| Hispanic | … | 2 (3.3) | … | … | |
| Other | 6 (7.7) | 3 (5) | … | … | |
| Unknown | 19 (24.4) | 18 (30) | … | … | |
| Health insurance, n (%) | |||||
| Public | 36 (46.2) | 29 (48.3) | .454 | … | … |
| Private | 20 (25.6) | 19 (31.7) | … | … | |
| No insurance | 5 (6.4) | 5 (8.3) | … | … | |
| Unknown | 17 (21.8) | 7 (11.7) | … | … | |
| Chronic comorbidities, n (%) | 65 (83.3) | 47 (78.3) | .514 | 1.383 | (.588, 3.253) |
| Acute comorbidities, n (%) | 10 (12.8) | 10 (16.7) | .628 | .735 | (.285, 1.900) |
| Symptoms at presentation, n (%) | |||||
| Cough (any) | 64 (87.7) | 41 (82) | .441 | 1.561 | (.572, 4.259) |
| Productive cough | 46 (63) | 31 (62) | 1.000 | 1.044 | (.497, 2.195) |
| Hemoptysis | 10 (13.7) | 12 (24) | .158 | .503 | (.198, 1.275) |
| Shortness of breath | 32 (43.8) | 22 (44.9) | 1.000 | .958 | (.462, 1.985) |
| Fever | 11 (15.1) | 5 (10) | .587 | 1.597 | (.519, 4.916) |
| Fatigue | 17 (23.3) | 9 (18) | .510 | 1.383 | (.561, 3.411) |
| Reported weight loss | 17 (23.3) | 10 (20) | .825 | 1.214 | (.504, 2.928) |
| Chest pain | 11 (16.7) | 4 (9.8) | .398 | 1.849 | (.547, 6.250) |
| Edema | 3 (4.1) | 3 (6.1) | .683 | .657 | (.127, 3.398) |
| Radiologic findings at diagnosis, n (%) | |||||
| Infiltrates/opacities | 21 (27.6) | 15 (27.8) | 1.000 | .993 | (.455, 2.164) |
| Single nodule | 2 (2.6) | 1 (1.9) | 1.000 | 1.432 | (.127, 16.209) |
| Multiple nodules | 45 (59.2) | 29 (53.7) | .592 | 1.251 | (.619, 2.530) |
| Cavitation | 22 (29.3) | 13 (24.1) | .552 | 1.309 | (.590, 2.907) |
| Single area bronchiectasis (unilobar) | 14 (18.4) | 6 (11.1) | .327 | 1.806 | (.646, 5.048) |
| Multifocal bronchiectasis | 34 (44.7) | 16 (29.6) | .101 | 1.922 | (.918, 4.024) |
| Ground-glass opacity | 10 (13.2) | 6 (11.1) | .792 | 1.212 | (.412, 3.563) |
| Tree-in-bud opacities | 32 (42.7) | 15 (29.4) | .137 | 1.786 | (.838, 3.805) |
| Scarring | 10 (13.3) | 13 (25) | .106 | .462 | (.185, 1.152) |
| Emphysema | 15 (20) | 13 (25.5) | .516 | .731 | (.313, 1.704) |
| Pleural thickening | 1 (1.4) | 4 (7.8) | .158 | .161 | (.017, 1.485) |
| Pleural effusion | 1 (1.4) | 1 (2.3) | 1.000 | .632 | (.039, 10.378) |
| Met ATS/IDSA diagnostic guidelines, n (%) | 62 (79.5) | 40 (67.8) | .166 | 1.841 | (.848, 3.994) |
| Duration of treatment, mean ± SD, m | 15.7 ± 7.0 | 17.8 ± 11.5 | .226 | .976 | (.938, 1.016) |
| Adherence to ATS/IDSA treatment guidelines, n (%) | 64 (85.3) | 33 (55.9) | .000 | 4.583 | (2.017, 10.411) |
| No. of antibiotics administered as initial therapy, n (%) | |||||
| 1 | … | 4 (6.8) | .006 | … | … |
| 2 | 5 (6.4) | 10 (16.9) | … | … | |
| ≥3 | 73 (93.6) | 45 (76.3) | … | … | |
| NTM type at diagnosis, n (%) | |||||
| MAC | 61 (78.2) | 51 (86.4) | .645 | … | … |
| M. kansasii | 9 (11.5) | 3 (5.1) | … | … | |
| M. abscessus | 2 (2.6) | 3 (5.1) | … | … | |
| M. szulgai | 1 (1.3) | … | … | … | |
| M. chelonae group | 1 (1.3) | … | … | … | |
| M. xenopi | 1 (1.3) | … | … | … | |
| Multiple | 3 (3.8) | 2 (3.4) | … | … | |
| Aspergillus coinfection at diagnosis, n (%) | 4 (5.1) | 5 (8.3) | .502 | .595 | (.153, 2.317) |
| Staphylococcus aureus coinfection at diagnosis, n (%) | 5 (6.4) | 2 (3.3) | .699 | 1.985 | (.372, 10.605) |
| Pseudomonas aeruginosa coinfection at diagnosis, n (%) | 7 (9) | 4 (6.7) | .756 | 1.380 | (.385, 4.952) |
| . | Cure (n = 78) . | No Cure (n = 60) . | P . | Odds Ratio . | 95% CI . |
|---|---|---|---|---|---|
| Age at presentation, median (IQR), y | 61.5 (54.0, 71.2) | 62.2 (55.0, 70.7) | .986 | 1.000 | (.977, 1.024) |
| Female, n (%) | 54 (69.2) | 40 (66.7) | .854 | 1.125 | (.547, 2.313) |
| BMI, median (IQR), kg/m2 | 22.4 (19.1, 24.7) | 22.1 (19.5, 25.7) | .467 | 1.026 | (.957, 1.098) |
| Race/ethnicity, n (%) | |||||
| Non-Hispanic white | 47 (60.3) | 35 (58.3) | .396 | … | … |
| Non-Hispanic black | 6 (7.7) | 2 (3.3) | … | … | |
| Hispanic | … | 2 (3.3) | … | … | |
| Other | 6 (7.7) | 3 (5) | … | … | |
| Unknown | 19 (24.4) | 18 (30) | … | … | |
| Health insurance, n (%) | |||||
| Public | 36 (46.2) | 29 (48.3) | .454 | … | … |
| Private | 20 (25.6) | 19 (31.7) | … | … | |
| No insurance | 5 (6.4) | 5 (8.3) | … | … | |
| Unknown | 17 (21.8) | 7 (11.7) | … | … | |
| Chronic comorbidities, n (%) | 65 (83.3) | 47 (78.3) | .514 | 1.383 | (.588, 3.253) |
| Acute comorbidities, n (%) | 10 (12.8) | 10 (16.7) | .628 | .735 | (.285, 1.900) |
| Symptoms at presentation, n (%) | |||||
| Cough (any) | 64 (87.7) | 41 (82) | .441 | 1.561 | (.572, 4.259) |
| Productive cough | 46 (63) | 31 (62) | 1.000 | 1.044 | (.497, 2.195) |
| Hemoptysis | 10 (13.7) | 12 (24) | .158 | .503 | (.198, 1.275) |
| Shortness of breath | 32 (43.8) | 22 (44.9) | 1.000 | .958 | (.462, 1.985) |
| Fever | 11 (15.1) | 5 (10) | .587 | 1.597 | (.519, 4.916) |
| Fatigue | 17 (23.3) | 9 (18) | .510 | 1.383 | (.561, 3.411) |
| Reported weight loss | 17 (23.3) | 10 (20) | .825 | 1.214 | (.504, 2.928) |
| Chest pain | 11 (16.7) | 4 (9.8) | .398 | 1.849 | (.547, 6.250) |
| Edema | 3 (4.1) | 3 (6.1) | .683 | .657 | (.127, 3.398) |
| Radiologic findings at diagnosis, n (%) | |||||
| Infiltrates/opacities | 21 (27.6) | 15 (27.8) | 1.000 | .993 | (.455, 2.164) |
| Single nodule | 2 (2.6) | 1 (1.9) | 1.000 | 1.432 | (.127, 16.209) |
| Multiple nodules | 45 (59.2) | 29 (53.7) | .592 | 1.251 | (.619, 2.530) |
| Cavitation | 22 (29.3) | 13 (24.1) | .552 | 1.309 | (.590, 2.907) |
| Single area bronchiectasis (unilobar) | 14 (18.4) | 6 (11.1) | .327 | 1.806 | (.646, 5.048) |
| Multifocal bronchiectasis | 34 (44.7) | 16 (29.6) | .101 | 1.922 | (.918, 4.024) |
| Ground-glass opacity | 10 (13.2) | 6 (11.1) | .792 | 1.212 | (.412, 3.563) |
| Tree-in-bud opacities | 32 (42.7) | 15 (29.4) | .137 | 1.786 | (.838, 3.805) |
| Scarring | 10 (13.3) | 13 (25) | .106 | .462 | (.185, 1.152) |
| Emphysema | 15 (20) | 13 (25.5) | .516 | .731 | (.313, 1.704) |
| Pleural thickening | 1 (1.4) | 4 (7.8) | .158 | .161 | (.017, 1.485) |
| Pleural effusion | 1 (1.4) | 1 (2.3) | 1.000 | .632 | (.039, 10.378) |
| Met ATS/IDSA diagnostic guidelines, n (%) | 62 (79.5) | 40 (67.8) | .166 | 1.841 | (.848, 3.994) |
| Duration of treatment, mean ± SD, m | 15.7 ± 7.0 | 17.8 ± 11.5 | .226 | .976 | (.938, 1.016) |
| Adherence to ATS/IDSA treatment guidelines, n (%) | 64 (85.3) | 33 (55.9) | .000 | 4.583 | (2.017, 10.411) |
| No. of antibiotics administered as initial therapy, n (%) | |||||
| 1 | … | 4 (6.8) | .006 | … | … |
| 2 | 5 (6.4) | 10 (16.9) | … | … | |
| ≥3 | 73 (93.6) | 45 (76.3) | … | … | |
| NTM type at diagnosis, n (%) | |||||
| MAC | 61 (78.2) | 51 (86.4) | .645 | … | … |
| M. kansasii | 9 (11.5) | 3 (5.1) | … | … | |
| M. abscessus | 2 (2.6) | 3 (5.1) | … | … | |
| M. szulgai | 1 (1.3) | … | … | … | |
| M. chelonae group | 1 (1.3) | … | … | … | |
| M. xenopi | 1 (1.3) | … | … | … | |
| Multiple | 3 (3.8) | 2 (3.4) | … | … | |
| Aspergillus coinfection at diagnosis, n (%) | 4 (5.1) | 5 (8.3) | .502 | .595 | (.153, 2.317) |
| Staphylococcus aureus coinfection at diagnosis, n (%) | 5 (6.4) | 2 (3.3) | .699 | 1.985 | (.372, 10.605) |
| Pseudomonas aeruginosa coinfection at diagnosis, n (%) | 7 (9) | 4 (6.7) | .756 | 1.380 | (.385, 4.952) |
Abbreviations: ATS/IDSA, American Thoracic Society/Infectious Diseases Society of America; BMI, body mass index; CI, confidence interval; IQR, interquartile range; MAC, Mycobacterium avium-intracellulare complex; NTM, nontuberculous mycobacteria.
| . | Cure (n = 78) . | No Cure (n = 60) . | P . | Odds Ratio . | 95% CI . |
|---|---|---|---|---|---|
| Age at presentation, median (IQR), y | 61.5 (54.0, 71.2) | 62.2 (55.0, 70.7) | .986 | 1.000 | (.977, 1.024) |
| Female, n (%) | 54 (69.2) | 40 (66.7) | .854 | 1.125 | (.547, 2.313) |
| BMI, median (IQR), kg/m2 | 22.4 (19.1, 24.7) | 22.1 (19.5, 25.7) | .467 | 1.026 | (.957, 1.098) |
| Race/ethnicity, n (%) | |||||
| Non-Hispanic white | 47 (60.3) | 35 (58.3) | .396 | … | … |
| Non-Hispanic black | 6 (7.7) | 2 (3.3) | … | … | |
| Hispanic | … | 2 (3.3) | … | … | |
| Other | 6 (7.7) | 3 (5) | … | … | |
| Unknown | 19 (24.4) | 18 (30) | … | … | |
| Health insurance, n (%) | |||||
| Public | 36 (46.2) | 29 (48.3) | .454 | … | … |
| Private | 20 (25.6) | 19 (31.7) | … | … | |
| No insurance | 5 (6.4) | 5 (8.3) | … | … | |
| Unknown | 17 (21.8) | 7 (11.7) | … | … | |
| Chronic comorbidities, n (%) | 65 (83.3) | 47 (78.3) | .514 | 1.383 | (.588, 3.253) |
| Acute comorbidities, n (%) | 10 (12.8) | 10 (16.7) | .628 | .735 | (.285, 1.900) |
| Symptoms at presentation, n (%) | |||||
| Cough (any) | 64 (87.7) | 41 (82) | .441 | 1.561 | (.572, 4.259) |
| Productive cough | 46 (63) | 31 (62) | 1.000 | 1.044 | (.497, 2.195) |
| Hemoptysis | 10 (13.7) | 12 (24) | .158 | .503 | (.198, 1.275) |
| Shortness of breath | 32 (43.8) | 22 (44.9) | 1.000 | .958 | (.462, 1.985) |
| Fever | 11 (15.1) | 5 (10) | .587 | 1.597 | (.519, 4.916) |
| Fatigue | 17 (23.3) | 9 (18) | .510 | 1.383 | (.561, 3.411) |
| Reported weight loss | 17 (23.3) | 10 (20) | .825 | 1.214 | (.504, 2.928) |
| Chest pain | 11 (16.7) | 4 (9.8) | .398 | 1.849 | (.547, 6.250) |
| Edema | 3 (4.1) | 3 (6.1) | .683 | .657 | (.127, 3.398) |
| Radiologic findings at diagnosis, n (%) | |||||
| Infiltrates/opacities | 21 (27.6) | 15 (27.8) | 1.000 | .993 | (.455, 2.164) |
| Single nodule | 2 (2.6) | 1 (1.9) | 1.000 | 1.432 | (.127, 16.209) |
| Multiple nodules | 45 (59.2) | 29 (53.7) | .592 | 1.251 | (.619, 2.530) |
| Cavitation | 22 (29.3) | 13 (24.1) | .552 | 1.309 | (.590, 2.907) |
| Single area bronchiectasis (unilobar) | 14 (18.4) | 6 (11.1) | .327 | 1.806 | (.646, 5.048) |
| Multifocal bronchiectasis | 34 (44.7) | 16 (29.6) | .101 | 1.922 | (.918, 4.024) |
| Ground-glass opacity | 10 (13.2) | 6 (11.1) | .792 | 1.212 | (.412, 3.563) |
| Tree-in-bud opacities | 32 (42.7) | 15 (29.4) | .137 | 1.786 | (.838, 3.805) |
| Scarring | 10 (13.3) | 13 (25) | .106 | .462 | (.185, 1.152) |
| Emphysema | 15 (20) | 13 (25.5) | .516 | .731 | (.313, 1.704) |
| Pleural thickening | 1 (1.4) | 4 (7.8) | .158 | .161 | (.017, 1.485) |
| Pleural effusion | 1 (1.4) | 1 (2.3) | 1.000 | .632 | (.039, 10.378) |
| Met ATS/IDSA diagnostic guidelines, n (%) | 62 (79.5) | 40 (67.8) | .166 | 1.841 | (.848, 3.994) |
| Duration of treatment, mean ± SD, m | 15.7 ± 7.0 | 17.8 ± 11.5 | .226 | .976 | (.938, 1.016) |
| Adherence to ATS/IDSA treatment guidelines, n (%) | 64 (85.3) | 33 (55.9) | .000 | 4.583 | (2.017, 10.411) |
| No. of antibiotics administered as initial therapy, n (%) | |||||
| 1 | … | 4 (6.8) | .006 | … | … |
| 2 | 5 (6.4) | 10 (16.9) | … | … | |
| ≥3 | 73 (93.6) | 45 (76.3) | … | … | |
| NTM type at diagnosis, n (%) | |||||
| MAC | 61 (78.2) | 51 (86.4) | .645 | … | … |
| M. kansasii | 9 (11.5) | 3 (5.1) | … | … | |
| M. abscessus | 2 (2.6) | 3 (5.1) | … | … | |
| M. szulgai | 1 (1.3) | … | … | … | |
| M. chelonae group | 1 (1.3) | … | … | … | |
| M. xenopi | 1 (1.3) | … | … | … | |
| Multiple | 3 (3.8) | 2 (3.4) | … | … | |
| Aspergillus coinfection at diagnosis, n (%) | 4 (5.1) | 5 (8.3) | .502 | .595 | (.153, 2.317) |
| Staphylococcus aureus coinfection at diagnosis, n (%) | 5 (6.4) | 2 (3.3) | .699 | 1.985 | (.372, 10.605) |
| Pseudomonas aeruginosa coinfection at diagnosis, n (%) | 7 (9) | 4 (6.7) | .756 | 1.380 | (.385, 4.952) |
| . | Cure (n = 78) . | No Cure (n = 60) . | P . | Odds Ratio . | 95% CI . |
|---|---|---|---|---|---|
| Age at presentation, median (IQR), y | 61.5 (54.0, 71.2) | 62.2 (55.0, 70.7) | .986 | 1.000 | (.977, 1.024) |
| Female, n (%) | 54 (69.2) | 40 (66.7) | .854 | 1.125 | (.547, 2.313) |
| BMI, median (IQR), kg/m2 | 22.4 (19.1, 24.7) | 22.1 (19.5, 25.7) | .467 | 1.026 | (.957, 1.098) |
| Race/ethnicity, n (%) | |||||
| Non-Hispanic white | 47 (60.3) | 35 (58.3) | .396 | … | … |
| Non-Hispanic black | 6 (7.7) | 2 (3.3) | … | … | |
| Hispanic | … | 2 (3.3) | … | … | |
| Other | 6 (7.7) | 3 (5) | … | … | |
| Unknown | 19 (24.4) | 18 (30) | … | … | |
| Health insurance, n (%) | |||||
| Public | 36 (46.2) | 29 (48.3) | .454 | … | … |
| Private | 20 (25.6) | 19 (31.7) | … | … | |
| No insurance | 5 (6.4) | 5 (8.3) | … | … | |
| Unknown | 17 (21.8) | 7 (11.7) | … | … | |
| Chronic comorbidities, n (%) | 65 (83.3) | 47 (78.3) | .514 | 1.383 | (.588, 3.253) |
| Acute comorbidities, n (%) | 10 (12.8) | 10 (16.7) | .628 | .735 | (.285, 1.900) |
| Symptoms at presentation, n (%) | |||||
| Cough (any) | 64 (87.7) | 41 (82) | .441 | 1.561 | (.572, 4.259) |
| Productive cough | 46 (63) | 31 (62) | 1.000 | 1.044 | (.497, 2.195) |
| Hemoptysis | 10 (13.7) | 12 (24) | .158 | .503 | (.198, 1.275) |
| Shortness of breath | 32 (43.8) | 22 (44.9) | 1.000 | .958 | (.462, 1.985) |
| Fever | 11 (15.1) | 5 (10) | .587 | 1.597 | (.519, 4.916) |
| Fatigue | 17 (23.3) | 9 (18) | .510 | 1.383 | (.561, 3.411) |
| Reported weight loss | 17 (23.3) | 10 (20) | .825 | 1.214 | (.504, 2.928) |
| Chest pain | 11 (16.7) | 4 (9.8) | .398 | 1.849 | (.547, 6.250) |
| Edema | 3 (4.1) | 3 (6.1) | .683 | .657 | (.127, 3.398) |
| Radiologic findings at diagnosis, n (%) | |||||
| Infiltrates/opacities | 21 (27.6) | 15 (27.8) | 1.000 | .993 | (.455, 2.164) |
| Single nodule | 2 (2.6) | 1 (1.9) | 1.000 | 1.432 | (.127, 16.209) |
| Multiple nodules | 45 (59.2) | 29 (53.7) | .592 | 1.251 | (.619, 2.530) |
| Cavitation | 22 (29.3) | 13 (24.1) | .552 | 1.309 | (.590, 2.907) |
| Single area bronchiectasis (unilobar) | 14 (18.4) | 6 (11.1) | .327 | 1.806 | (.646, 5.048) |
| Multifocal bronchiectasis | 34 (44.7) | 16 (29.6) | .101 | 1.922 | (.918, 4.024) |
| Ground-glass opacity | 10 (13.2) | 6 (11.1) | .792 | 1.212 | (.412, 3.563) |
| Tree-in-bud opacities | 32 (42.7) | 15 (29.4) | .137 | 1.786 | (.838, 3.805) |
| Scarring | 10 (13.3) | 13 (25) | .106 | .462 | (.185, 1.152) |
| Emphysema | 15 (20) | 13 (25.5) | .516 | .731 | (.313, 1.704) |
| Pleural thickening | 1 (1.4) | 4 (7.8) | .158 | .161 | (.017, 1.485) |
| Pleural effusion | 1 (1.4) | 1 (2.3) | 1.000 | .632 | (.039, 10.378) |
| Met ATS/IDSA diagnostic guidelines, n (%) | 62 (79.5) | 40 (67.8) | .166 | 1.841 | (.848, 3.994) |
| Duration of treatment, mean ± SD, m | 15.7 ± 7.0 | 17.8 ± 11.5 | .226 | .976 | (.938, 1.016) |
| Adherence to ATS/IDSA treatment guidelines, n (%) | 64 (85.3) | 33 (55.9) | .000 | 4.583 | (2.017, 10.411) |
| No. of antibiotics administered as initial therapy, n (%) | |||||
| 1 | … | 4 (6.8) | .006 | … | … |
| 2 | 5 (6.4) | 10 (16.9) | … | … | |
| ≥3 | 73 (93.6) | 45 (76.3) | … | … | |
| NTM type at diagnosis, n (%) | |||||
| MAC | 61 (78.2) | 51 (86.4) | .645 | … | … |
| M. kansasii | 9 (11.5) | 3 (5.1) | … | … | |
| M. abscessus | 2 (2.6) | 3 (5.1) | … | … | |
| M. szulgai | 1 (1.3) | … | … | … | |
| M. chelonae group | 1 (1.3) | … | … | … | |
| M. xenopi | 1 (1.3) | … | … | … | |
| Multiple | 3 (3.8) | 2 (3.4) | … | … | |
| Aspergillus coinfection at diagnosis, n (%) | 4 (5.1) | 5 (8.3) | .502 | .595 | (.153, 2.317) |
| Staphylococcus aureus coinfection at diagnosis, n (%) | 5 (6.4) | 2 (3.3) | .699 | 1.985 | (.372, 10.605) |
| Pseudomonas aeruginosa coinfection at diagnosis, n (%) | 7 (9) | 4 (6.7) | .756 | 1.380 | (.385, 4.952) |
Abbreviations: ATS/IDSA, American Thoracic Society/Infectious Diseases Society of America; BMI, body mass index; CI, confidence interval; IQR, interquartile range; MAC, Mycobacterium avium-intracellulare complex; NTM, nontuberculous mycobacteria.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
